Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resistant hypertension~* Diabetes mellitus~Exclusion Criteria:~* T2DM with overt acute/chronic complications,~* serum potassium ≥ 5.5 mmol/l,~* estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight,~* absolute contraindication to any of the drug regimen of the trial,~* and current aldosterone antagonist treatment or cessation within the last 15 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low dose Spironolactone (Type: EXPERIMENTAL): Add-on low dose 25 mg Spironolactone to current hypertension treatment
- Routine (Type: ACTIVE_COMPARATOR): Routine intensification of anti hypertensive treatment based on existing guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).